ClinicalTrials.gg
CompletedNCT07459166Updated Nov 10, 2026

A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade

A Phase 2 interventional study of Naloxone Hydrochloride and Fentanyl in Fentanyl Overdose and Fentanyl Poisoning, sponsored by Clear Scientific, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Clear Scientific, Inc. · Phase 2, Interventional, and Treatment

Updated Nov 10, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Poisoning with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Poisoning · United States.

Enrollment
6th of 11
16 · median 16
Started
2026
the only one that year
Phase 2
Only one
of the 14
Registered
14th of 14
by date
Lead sponsor
1 of 14
Clear Scientific, Inc.

Among the 14 studies in Poisoning with a site in United States, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 2, and was the 14th registered.

Poisoning

98 studies on the registry are indexed under Poisoning; 16 are open to participants now.

Browse Poisoning studies →

Open to participants now

1 of the 14 studies in Poisoning with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Poisoning studies recruiting now, 6 set no upper age limit and 2 stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Poisoning with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CS-1103 (1,000 mg), given by intravenous (IV) infusion in healthy participants in the presence of a clinically relevant dose of fentanyl (200 μg, IV), with naloxone blockade (400 μg, IV).

03

Conditions studied

  • Fentanyl Overdose
  • Fentanyl Poisoning

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Major Inclusion Criteria:

  1. Healthy participants aged 18 to 55 years, inclusive;
  2. Have prior experience with opioids, such as from a dental procedure, chronic pain management, or previous inpatient surgical procedure;
  3. A between 18.0 to 30.0 kg/m2, inclusive, and a minimum body weight of 56 kg;
  4. Females must not be lactating and must have a negative pregnancy test during screening and admission.

Major Exclusion Criteria:

  1. Estimated \<90 mL/min/1.73 m2;
  2. History of cardiovascular disease;
  3. History of any disease or disorder which, in the opinion of the Investigator, may interfere with safe study participation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants receive naloxone blockade (400 μg, IV), followed by fentanyl (200 μg, IV), followed by placebo (saline).

    Drug: Naloxone Hydrochloride · Drug: Fentanyl · Drug: Sterile Saline

  • Active comparator
    Active

    Participants receive naloxone blockade (400 μg, IV), followed by fentanyl (200 μg, IV), followed by CS-1103 (1,000 mg, IV).

    Drug: Naloxone Hydrochloride · Drug: Fentanyl · Drug: CS-1103

Interventions

  • Naloxone for intravenous administration

  • Fentanyl for intravenous administration

  • DrugSterile Saline

    Sterile Saline for intravenous administration

  • CS-1103 for intravenous administration

06

What researchers measure

Primary outcomes

  1. Number of participants with CS-1103-related adverse events (AEs) assessed by physical examinations

    Physical examinations

    Time frame: 3 days plus follow-up on Day 10

  2. Number of participants with CS-1103-related adverse events (AEs) assessed by electrocardiograms (ECGs)

    Digital 12-lead electrocardiograms (ECGs). Any correlation between CS-1103 plasma concentrations and changes in QT intervals will be noted

    Time frame: 3 days plus follow-up on Day 10

  3. Number of participants with CS-1103-related adverse events (AEs) assessed by vital signs

    Blood pressure, pulse rate, respiratory rate, oxygen saturation, and body temperature

    Time frame: 3 days plus follow-up on Day 10

  4. Number of participants with CS-1103-related adverse events (AEs) assessed by laboratory parameters

    Clinical chemistry, hematology, coagulation, and urinalysis

    Time frame: 3 days plus follow-up on Day 10

  5. Time course of CS-1103 blood and urine concentrations

    Measurement of plasma and urine concentrations of CS-1103

    Time frame: 48 hours

  6. Time course and magnitude of urine excretion of fentanyl

    Measurement of concentration of fentanyl in urine

    Time frame: 48 hours

Secondary outcomes

  1. Effect of CS-1103 and fentanyl on QT interval

    Concentration-QT correlation performed on baseline-corrected QTcF time-matched with PK for fentanyl and CS-1103 in plasma

    Time frame: 48 hours

  2. Effect of CS-1103 on the naloxone plasma and urine PK, if any

    Measurement of standard urine and plasma PK parameters between placebo and CS-1103 treated participants

    Time frame: 48 hours

07

Study locations

1 site
  • California Clinical Trials Medical Group
    Glendale, California 91206, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2026 to primary completion in Jul 2026, 1 month.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jul 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 9, 2026
StartActual
May 28, 2026
Primary completionActual
Jul 15, 2026
CompletionActual
Jul 22, 2026was Oct 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 10, 2026
Primary completion
Jul 22, 2026→Jul 15, 2026
Nov 10, 2026
Study completion
Oct 2026→Jul 22, 2026 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Completed
    Primary completion Jul 22, 2026→Jul 15, 2026
    Study completion Oct 2026→Jul 22, 2026 (now actual)
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07459166
Lead sponsor
Clear Scientific, Inc.
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
May 28, 2026
Primary completion
Jul 15, 2026
Completion
Jul 22, 2026
Last update
Nov 10, 2026

Study contacts

Xinhua Li, Ph.D.
principal investigator · Clear Scientific, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CS-1103

Start the discussion